What they did: They transected the quadriceps (front thigh) of rats and divided them into three groups: Control, no drugs Dexamethasone, a potent corticosteroid that is known to impair healing Dexamethasone + BPC-157 What they found: Dexamethasone group: 50 % worse healing than control (confirmed negative effect of steroids) Dexamethasone + BPC-157 group: healing at the level of controls without steroids Why it matters: This is a highly clinically relevant finding
The first approved therapy, Resmetirom (Rezdiffra)developed by Madrigal Pharmaceuticalsreceived FDA approval in March 2024
Supports joint function and contributes to recovery following physical activity
Patients consistently report significant improvements in cardiovascular health, with reduced blood pressure, improved cholesterol profiles, and enhanced heart function
Amer Academy Dermat Meeting, February 2002, Abstract P68, P69 Leyden J., Stephens T., Finkey M., Barkovic S